Lilly agrees to buy U.S. biotech Morphic in US$3.2 billion deal
Eli Lilly & Co. agreed to buy U.S. gut-drug maker Morphic Holding Inc. for about US$3.2 billion, plowing some of the proceeds from obesity blockbuster Zepbound into its experimental pipeline. ...
Read more